Company Description
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs.
It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel.
The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016.
Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 4, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Rami Elghandour |
Contact Details
Address: 800 Bridge Parkway Redwood City, California 94065 United States | |
| Phone | 240-327-0603 |
| Website | arcellx.com |
Stock Details
| Ticker Symbol | ACLX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001786205 |
| CUSIP Number | 03940C100 |
| ISIN Number | US03940C1009 |
| Employer ID | 47-2855917 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Rami Elghandour | Chairman of the Board, Chief Executive Officer and President |
| Michelle Lim Gilson | Chief Financial Officer |
| Dr. Christopher R. Heery M.D. | Chief Medical Officer |
| Narinderjeet Singh M.S. | Chief Technical Officer |
| David Tice Ph.D. | Chief Scientific Officer |
| Myesha Lacy | Chief Investor and Communications Officer |
| Maryam Abdul-Kareem J.D., M.S. | General Counsel and Chief Legal Officer |
| Kate Aiken | Chief People Officer |
| Neeraj P. Teotia | Chief Commercial Officer |
| Aileen Fernandes | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | ARS | Filing |
| Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 1, 2024 | 144 | Filing |
| Mar 25, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 22, 2024 | 144 | Filing |
| Mar 21, 2024 | 144 | Filing |
| Mar 21, 2024 | 144 | Filing |
| Mar 18, 2024 | 144 | Filing |